title: Optimizing preclinical study design in oncology research.
abstract: The current drug development pathway in oncology research has led to a large attrition rate for new drugs, in part due to a general lack of appropriate preclinical studies that are capable of accurately predicting efficacy and/or toxicity in the target population. Because of an obvious need for novel therapeutics in many types of cancer, new compounds are being investigated in human Phase I and Phase II clinical trials before a complete understanding of their toxicity and efficacy profiles is obtained. In fact, for newer targeted molecular agents that are often cytostatic in nature, the conventional preclinical evaluation used for traditional cytotoxic chemotherapies utilizing primary tumor shrinkage as an endpoint may not be appropriate. By utilizing an integrated pharmacokinetic/pharmacodynamic approach, along with proper selection of a model system, the drug development process in oncology research may be improved leading to a better understanding of the determinants of efficacy and toxicity, and ultimately fewer drugs that fail once they reach human clinical trials.
authors.affiliation: Flint Animal Cancer Center, Department of Clinical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523-1620, United States. Luke.Wittenburg@colostate.edu
authors.forename: Luke A
authors.initials: LA
authors.lastname: Wittenburg
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Gustafson
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008658:Inactivation, Metabolic; D011506:Proteins / Q000737:chemistry / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D011506:Proteins